We are excited to welcome Abid to our executive team,” said Jeff Glazier, Chief Executive Officer of General Oncology. “With deep expertise in strategic financial leadership, capital raising, and ...

New compelling results demonstrate 18 months of both sustained reduction in immunoglobulin G antibodies and sustained improvement in gMG symptoms in pivotal Vivacity-MG3 study and open label extension ...

Explore JANX's promising early data in prostate cancer immunotherapy. Understand market challenges, buyout rumors, and ...

Rhythm Pharma (RYTM) stock rises as lead asset setmelanotide succeeds in a Phase 3 trial for a rare obesity type, causing an ...

The current macro environment appears grim, given the uncertainty around the global trade war, along with ongoing ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...